HK1154385A1 - Novel uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof - Google Patents

Novel uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof

Info

Publication number
HK1154385A1
HK1154385A1 HK11108513.8A HK11108513A HK1154385A1 HK 1154385 A1 HK1154385 A1 HK 1154385A1 HK 11108513 A HK11108513 A HK 11108513A HK 1154385 A1 HK1154385 A1 HK 1154385A1
Authority
HK
Hong Kong
Prior art keywords
salt
inhibitory activity
uracil compound
deoxyuridine triphosphatase
novel uracil
Prior art date
Application number
HK11108513.8A
Other languages
English (en)
Chinese (zh)
Inventor
福岡正哲
橫川達史
宫原成司
宫腰均
矢野稚子
田口淳子
高尾彌生
Original Assignee
大鵬藥品工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大鵬藥品工業株式會社 filed Critical 大鵬藥品工業株式會社
Publication of HK1154385A1 publication Critical patent/HK1154385A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK11108513.8A 2008-06-03 2011-08-15 Novel uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof HK1154385A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008146334 2008-06-03
PCT/JP2009/002481 WO2009147843A1 (ja) 2008-06-03 2009-06-02 ヒトデオキシウリジントリホスファターゼ阻害活性を有する新規ウラシル化合物又はその塩

Publications (1)

Publication Number Publication Date
HK1154385A1 true HK1154385A1 (en) 2012-04-20

Family

ID=41397926

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108513.8A HK1154385A1 (en) 2008-06-03 2011-08-15 Novel uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof

Country Status (21)

Country Link
US (1) US8530490B2 (xx)
EP (1) EP2295414B1 (xx)
JP (1) JP4688975B2 (xx)
KR (1) KR101384940B1 (xx)
CN (1) CN102056905B (xx)
AU (1) AU2009254656B2 (xx)
BR (1) BRPI0913590B1 (xx)
CA (1) CA2726579C (xx)
CY (1) CY1113244T1 (xx)
DK (1) DK2295414T3 (xx)
ES (1) ES2392220T3 (xx)
HK (1) HK1154385A1 (xx)
HR (1) HRP20120820T1 (xx)
MX (1) MX2010013275A (xx)
MY (1) MY149180A (xx)
PL (1) PL2295414T3 (xx)
PT (1) PT2295414E (xx)
RU (1) RU2495873C2 (xx)
SI (1) SI2295414T1 (xx)
TW (1) TWI466871B (xx)
WO (1) WO2009147843A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883759B2 (en) * 2009-11-30 2014-11-11 Taiho Pharmaceutical Co., Ltd. Anti-tumor effect potentiator
SG10202010626PA (en) * 2011-03-31 2020-11-27 Schaefer Konstanze Perfluorinated compounds for the non-viral transfer of nucleic acids
US9809571B2 (en) 2013-01-07 2017-11-07 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2015103489A1 (en) 2014-01-03 2015-07-09 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
WO2016175324A1 (ja) * 2015-04-30 2016-11-03 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
WO2016178416A1 (ja) 2015-05-01 2016-11-10 大鵬薬品工業株式会社 ウラシル化合物の新規結晶
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
EA037990B1 (ru) 2015-07-08 2021-06-21 Св6 Терапьютикс (Най) Лимитед Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US11612653B2 (en) 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098209A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
BR112022026247A2 (pt) 2020-06-26 2023-01-17 Cv6 Therapeutics Ni Ltd Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
CN111763176A (zh) * 2020-07-10 2020-10-13 常州制药厂有限公司 一种GnRH受体拮抗剂关键中间体及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
ATE245631T1 (de) * 1995-03-29 2003-08-15 Taiho Pharmaceutical Co Ltd Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
RU2102390C1 (ru) * 1996-06-06 1998-01-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством МЗМП России N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
JP2002028486A (ja) * 2000-07-14 2002-01-29 Toyobo Co Ltd アルデヒド類吸着分解剤及びその製造方法
JP2002284686A (ja) * 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
AU2003218933A1 (en) 2002-04-17 2003-11-03 Affinium Pharmaceuticals, Inc. Purified dutpase from helicobacter pylori
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
JP4534122B2 (ja) * 2003-12-26 2010-09-01 トヨタ自動車株式会社 ハイブリッドシステム
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
WO2008016522A2 (en) * 2006-07-24 2008-02-07 Gilead Sciences, Inc. Hiv reverse transcriptase inhibitors
US8883759B2 (en) * 2009-11-30 2014-11-11 Taiho Pharmaceutical Co., Ltd. Anti-tumor effect potentiator

Also Published As

Publication number Publication date
CY1113244T1 (el) 2016-04-13
BRPI0913590B1 (pt) 2021-07-06
AU2009254656B2 (en) 2013-07-18
ES2392220T3 (es) 2012-12-05
US20110082163A1 (en) 2011-04-07
KR101384940B1 (ko) 2014-04-11
EP2295414A1 (en) 2011-03-16
AU2009254656A2 (en) 2011-01-13
KR20110013427A (ko) 2011-02-09
RU2010154425A (ru) 2012-07-20
BRPI0913590A2 (pt) 2015-10-20
CN102056905B (zh) 2014-03-26
TW201000452A (en) 2010-01-01
EP2295414A4 (en) 2011-09-14
PT2295414E (pt) 2012-11-30
HRP20120820T1 (hr) 2012-11-30
CA2726579A1 (en) 2009-12-10
DK2295414T3 (da) 2012-10-22
SI2295414T1 (sl) 2012-12-31
JP4688975B2 (ja) 2011-05-25
PL2295414T3 (pl) 2013-02-28
US8530490B2 (en) 2013-09-10
AU2009254656A1 (en) 2009-12-10
TWI466871B (zh) 2015-01-01
EP2295414B1 (en) 2012-09-26
WO2009147843A1 (ja) 2009-12-10
CA2726579C (en) 2015-02-17
RU2495873C2 (ru) 2013-10-20
JPWO2009147843A1 (ja) 2011-10-27
MY149180A (en) 2013-07-31
CN102056905A (zh) 2011-05-11
MX2010013275A (es) 2011-03-15

Similar Documents

Publication Publication Date Title
HK1154385A1 (en) Novel uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof
EP2172453A4 (en) COMPOUND HAVING 11 ß-HSD1 INHIBITION ACTIVITY
ZA201002608B (en) Azolecarboxamide compound or salt thereof
EP1854793A4 (en) NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
IL210195A0 (en) Benzoxazines, benzothazines, and related compounds having nos inhibitory activity
TWI340645B (en) Solution for tissue adhesion prevention
EP2065369A4 (en) UREA CONNECTION OR SALT THEREOF
EP2231624A4 (en) TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR
EP2116269A4 (en) BLOOD CLEANING SYSTEM
GB0703417D0 (en) Electro-surgical systems
IL208638A0 (en) 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
ZA201005210B (en) Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
GB0714029D0 (en) Lantibiotic-based compounds having antimicrobial activity
ZA200707227B (en) Novel aminopyridine compound with syk inhibitory activity
EP2121739A4 (en) NOVEL POLYPEPTIDE HAVING ANTITUMOR ACTIVITY
IL212403A0 (en) Carbamate compound or salt thereof
EP2149561A4 (en) TETRAHYDROISOCHINOLIN-1-ON DERIVATIVE OR SALT THEREOF
PL2209458T3 (pl) Kompozycje do traktowania skóry
IL251655A0 (en) 6,2-diamino-pyrimidin-5-yl-carboxamides as inhibitors of syk or jak kinases
IL184779A0 (en) Novel pyrimidine nucleoside compound or salt thereof
EP2168947A4 (en) NOVEL COMPOUND HAVING SECRETASE INHIBITING ACTIVITY
ZA201103269B (en) COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY
GB0606921D0 (en) Skin dressing
EP2017279A4 (en) NEW AMINO-PYRIDINE DERIVATIVE WITH AURORA A SELECTIVE HEMORATIVE EFFECT
GB0710260D0 (en) Otter predation defence system